Rotavirus Vaccine
Mechanism :
A live vaccine that replicates in the small intestine and promotes active immunity to rotavirus gastroenteritis. Rotarix is specifically indicated for prevention of rotavirus gastroenteritis caused by serotypes G1, G3, G4, and G9 and RotaTeq is specifically indicated for prevention of rotavirus gastroenteritis caused by serotypes G1, G2, G3, G4, and G9.
Indication :
- Rotavirus gastroenteritis prevention
- Rotarix: Prevention of rotavirus gastroenteritis in infants 6 to 24 weeks of age when administered as a 2-dose series.
- RotaTeq: Prevention of rotavirus gastroenteritis in infants 6 to 32 weeks of age when administered as a 3-dose series.
Dosing :
Infants 6 to 24 weeks of age:
Rotarix:
A total of two 1 mL doses, the first dose given at 6 weeks of age, followed by the second dose given ≥4 weeks later. The 2-dose series should be completed by 24 weeks of age.
RotaTeq:
Given in 3 doses administered at 2, 4, and 6 months of age. The first dose can be given at 6 weeks to 14 weeks 6 days of age. The series should not be started in infants ≥15 weeks. The final dose in the series should be administered by 8 months of age. The minimum interval between doses is 4 weeks.
Adverse Effect :
Irritability, diarrhea, vomiting, otitis media, fussiness, flatulence, bronchospasm.
Interaction :
Corticosteroids: May enhance the adverse/toxic effect of live vaccines.
Immunosuppressants: May enhance the adverse/toxic effect of live vaccines.
Hepatic Dose :
No dosage adjustments are recommended